Project Grant R44DK142483
Award Date 9/10/25
Completion Date 6/30/27
Dollars Obligated $752K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94704, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $773,112 Project Grant to Rockefeller University on September 5, 2025 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to investigate the mechanisms of transcriptional control in adipocyte formation and function through nuclear receptor coactivators. The research aims to provide a better understanding of dysregulation in energy storage...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- The U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $222,500 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the Beckman Research Institute of the City of Hope. The grant supports research to understand how conjugated bile acids regulate metabolism after bariatric surgery, with the goal of developing safer and more affordable treatments for obesity and fatty liver disease. Key activities include...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, awarded a $728,801 Project Grant to the Regents of the University of Michigan under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant funds a 5-year project to test a novel weight navigation program aimed at overcoming barriers to obesity treatment in primary care settings. The project seeks to improve utilization of effective...
- This $315,342 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), to Velum Inc., a pharmaceutical research company based in Cambridge, Massachusetts. The grant supports the development of a novel weight loss drug centered on the peptide hormone Peptide YY (PYY). The goal is to create a chimeric triagonist molecule that combines the effects of PYY...
- This Project Grant award of $830,500.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research program) supports research investigating the role of glycosphingolipids in kidney disease associated with diabetes and obesity. The key objectives are to: Test whether inhibiting glucosylceramide synthesis in podocytes, renal tubules, or the immune system can prevent progression of kidney disease in mouse...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $3,145,056 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Duke University. The project aims to collect real-world evidence on the use of anti-obesity medications (AOMs) in adolescents, examining the reach, effectiveness, and potential unintended consequences of these treatments within clinical settings. The 4-year project will recruit a cohort of...
- This $2,638,760.00 Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research aims to investigate a novel mechanism involving the metabolite rhodoquinone (RQ) and its potential role in improving mitochondrial function and mitigating metabolic diseases caused by obesity. Specifically, the project will elucidate how the RQ/fumarate...
- This federal Project Grant award of $350,000 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The objective is to validate the use of AVGN7 (rAAV6:SMAD7), a gene therapeutic, for treating obesity and type 2 diabetes mellitus (T2DM). The key products or services to be delivered include: (1) Demonstrating that AVGN7 can restore lean body mass and insulin...